Drugmakers Turn to Data Mining to Avoid Expensive Drug Trials

Pfizer, Johnson & Johnson and Amgen are among the drugmakers that are trying to win drug approvals by parsing vast data sets of electronic medical records, shifting away from lengthy, and costly, clinical trials.